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Despite recent advances in understanding the genetic bases of microcephaly, a large number of cases of microcephaly remain unex-
plained, suggesting that many microcephaly syndromes and associated genes have yet to be identified. Here, we report mutations in
PYCR2, which encodes an enzyme in the proline biosynthesis pathway, as the cause of a unique syndrome characterized by postnatal
microcephaly, hypomyelination, and reduced cerebral white-matter volume. Linkage mapping and whole-exome sequencing identified
homozygous mutations (c.355C>T [p.Arg119Cys] and c.751C>T [p.Arg251Cys]) in PYCR2 in the affected individuals of two consan-
guineous families. A lymphoblastoid cell line from one affected individual showed a strong reduction in the amount of PYCR2.
When mutant cDNAs were transfected into HEK293FT cells, both variant proteins retained normal mitochondrial localization but
had lower amounts than the wild-type protein, suggesting that the variant proteins were less stable. A PYCR2-deficient HEK293FT
cell line generated by genome editing with the clustered regularly interspaced short palindromic repeat (CRISPR)-Cas9 system showed
that PYCR2 loss of function led to decreased mitochondrial membrane potential and increased susceptibility to apoptosis under oxida-
tive stress. Morpholino-based knockdown of a zebrafish PYCR2 ortholog, pycr1b, recapitulated the human microcephaly phenotype,
whichwas rescued by wild-type human PYCR2mRNA, but not bymutantmRNAs, further supporting the pathogenicity of the identified
variants. Hypomyelination and the absence of lax, wrinkly skin distinguishes this condition from that caused by previously reported
mutations in the gene encoding PYCR2’s isozyme, PYCR1, suggesting a unique and indispensable role for PYCR2 in the human CNS
during development.Introduction
Microcephaly is a condition in which the brain fails to
achieve normal size.1,2 The etiology of microcephaly is
highly heterogeneous and includes environmental and
genetic causes.3 Underlying pathogenic mechanisms in ge-
netic microcephaly are also diverse. Defects in centro-
somes and mitotic spindles4,5 and DNA-repair defects6
typically manifest with microcephaly at birth (congenital
microcephaly). On the other hand, degenerative condi-
tions, including inborn errors of metabolism, are often
associated with the development of microcephaly after
birth (postnatal microcephaly).1 In rare instances, micro-
cephaly can be associated with insufficient formation
of myelin, a condition known as hypomyelination.7
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The Amdromes have recently been identified, there are still many
cases with an unknown etiology.8 The differential diag-
nosis of microcephaly with hypomyelination includes
Pelizaeus-Merzbacher disease (MIM 312080), due to
mutations in PLP1 (MIM 300401),9,10 and hypomyelinat-
ing leukoencephalopathy 6 (MIM 612438), due to muta-
tions in TUBB4A (MIM 602662).11 In addition, inborn
errors of metabolism, such as phosphoglycerate dehydro-
genase deficiency (MIM 601815)12,13 and severe 5,10-
methylenetetrahydrofolate reductase deficiency (MIM
236250),3,14 are also important causes of microcephaly
with hypomyelination.
In this study, we investigated children (from two
consanguineous families) with a unique presentation of
microcephaly, hypomyelination, and reduced white-mat-
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Figure 1. Pedigrees Studied and Find-
ings from Brain MRI of the Affected Indi-
viduals
(A) Pedigree structure of the studied fam-
ilies (MR900 and MC27800). Shaded sym-
bols indicate affected individuals.
(B) Facial pictures of the affected individ-
uals in family MR900.
(C) MRI findings of the affected individ-
uals. T2-weighted axial images (top row)
and T1-weighted sagittal images (bottom
row) are shown. The ages at imaging
were 4 years and 0 months (MR901), 3
years and 4 months (MR902), 2 years
and 7 months, (MR27801), 1 year and
10 months (MC27802), and 3 years
and 1 month (control subject). All affected
individuals showed microcephaly, hypo-
myelination, reduced white-matter vol-
ume, a thin corpus callosum, and a
mildly thin brain stem. The scale bar repre-
sents 5 cm.an enzyme in the proline biosynthesis pathway, as under-
lying this syndrome.Material and Methods
Human Studies
This study was approved by the institutional review board of
Boston Children’s Hospital and equivalent committees of the
other participating institutions. Written informed consent was
obtained from all participants or their legal guardians.
Genome-wide SNP Genotyping and Linkage Analysis
Genome-wide SNP genotyping was performed for all indi-
viduals shown in Figures 1A and 1B by either the Illumina
HumanOmniExpress BeadChip array (for family MC27800) or
the Affymetrix Genome-Wide Human SNP Array 6.0 (for family
MR900) according to the manufacturers’ instructions. Combined
genome-wide LOD scores for the two families were calculated
with high-quality SNPs shared between the Illumina and Affyme-
trix arrays. PLINK15 was used to reduce linkage disequilibrium
between markers, and MERLIN16 was used to remove genotyping
errors and calculate LOD scores under the assumption of an auto-
somal-recessive mode of inheritance with 100% penetrance and a
disease allele prevalence of 0.0001.
Whole-Exome Sequencing and Sanger Sequencing
Coding regions were captured with Illumina TruSeq enrichment
(62 Mb) with sequencing on an Illumina HiSeq with 101-bp
paired-end reads. Sequencing of individual MR901 yielded 14 Gb
of sequencing (resulting in 203 coverage of 86.7% of the target re-
gion), and sequencing of individual MC27801 yielded 12 Gb of
sequence (resulting in 203 coverage of 84.8% of the target region).
Reads marked as duplicates by Picard (v.1.101) were excluded
before mapping to the human genome reference sequence
(GRCh37/hg19). The sequences were aligned to the reference
sequence with the Burrows-Wheeler Aligner, and variants were
called with mpileup (SAMtools). The Variant Explorer pipeline710 The American Journal of Human Genetics 96, 709–719, May 7, 2developed by the authors (K.S.-A and K.M.) was used for anno-
tating all variants according to minor-allele-frequency data from
the NHLBI Exome Sequencing Project Exome Variant Server
(September 2013), Complete Genomics (February 2012), dbSNP
(134–137), and 1000 Genomes (May 2012). Sanger sequencing
of candidate variants was performed according to standard proto-
col. Primers were designed with Primer3, and their sequences are
listed in Table S1.RNA Sequencing
mRNA sequencing data from human fetal (Carnegie stage 18)
cerebral cortex was obtained as previously described.17Lymphoblastoid Cell Lines
Epstein-Barr-virus-transformed lymphoblastoid cell lines from one
affected individual (MR901), his father (MR904), and one control
subject were cultured in DMEMwith 15% fetal bovine serum (FBS)
and 1% v/v penicillin-streptomycin solution. The cell lines were
grown in 5% CO2 at 37
C. For immunoblotting, cells were
extracted with M-PER mammalian protein-extraction reagent
(Thermo Scientific) according to the manufacturer’s protocol.Molecular Cloning
Human PYCR2 cDNA with no stop codon was synthesized as a
double-strand genomic block (Integrated DNA Technologies)
with an N-terminal overhang. The gene block was cloned into
the pcDNA3.2/V5/GW-D-TOPO vector (Life Technologies) with a
C-terminal V5 tag with the use of a TOPO cloning site. PYCR2
point mutations, c.355C>T (p.Arg119Cys) and c.751C>T
(p.Arg251Cys), were introduced with the QuikChange II Site-
Directed Mutagenesis Kit (Agilent Technologies). For generating
additional PYCR2 cDNA constructs for immunoprecipitation, the
V5 tag was replaced with an HA tag by PCR, and the product
was subcloned into the pcDNA 3.1 vector (Life Technologies).
For quantifying the level of exogenous PYCR2, Lipofectamin2000
(Life Technologies) was used to transfect HEK293FT cells (Invitro-
gen) with equal amounts of human PYCR2 expression vectors015
along with EGFP expression vector (pEGFP-C1, Clontech). The
cells were cultured in DMEM with 10% FBS and 1% v/v peni-
cillin-streptomycin solution. All cell lines were grown in 5% CO2
at 37C. The transfected cells were cultured for 48 hr and then
analyzed by immunoblot or immunofluorescence.Genome Editing Using the CRISPR-Cas9 System
To introduce genomic alternations at the PYCR2 locus in the
HEK293FT cell line, we performed genome editing with the clus-
tered regularly interspaced short palindromic repeat (CRISPR)-
Cas9 system.18 A 20-nt guide RNA (gRNA) sequence (50-GCCCT
GCACTTTCTAGAGAG-30) was designed to target double-strand
breaks at PYCR2 exon 6 andwas cloned into a full U6 promoter site
next to a protospacer-adjacent motif (50-NGG-30). pSpCas9(BB)-
2A-GFP plasmids (PX459, Addgene) were cultured in lysogeny
broth containing ampicillin and purified. With the Fugene HD
(Promega) transfection reagent, HEK293FT cells were transfected
with 1 mg of SpCas9 plasmid and 1 mg of gRNA plasmid in 6-well
plates. Forty-eight hours after transfection, cells were sorted with
GFP signal by fluorescence-activated cell sorting. Sorted cells
were cultured in 10-cm plates until they formed single-cell col-
onies, which were then manually picked and cultured in 96-well
dishes until they were 100% confluent. DNA was extracted from
each colony (QuickExtract DNA Extraction Solution, Epicenter),
and the targeted genomic region was sequenced. Primer sequences
used for Sanger sequencing are listed in Table S1.Immunofluorescence Analysis
For mitochondrial labeling, cultured cells were washed with
37C PBS once and incubated with an X-rosamine derivative
(MitoTracker, Life Technologies) at a concentration of 100 nM
for 30 min without FBS. For immunofluorescence, cells were
washed in PBS with glycine (PBS-G) twice. Cells were fixed in
4% (w/v) paraformaldehyde in PBS for 15 min and permeabilized
with 0.1% (w/v) Triton X-100 in PBS for 5 min at room tempera-
ture. Cells were then incubated overnight at 4C in PBS with 3%
BSA and antibodies to PYCR2 (LS-C115748, LsBio) or V5 (R960-
25, Life Technologies) and were visualized with immunoglobulin
G Alexa Fluor 488 and 594 conjugates (Life Technologies). DNA
was counterstained with Hoechst 33342, and cells were mounted
in Fluoromount-G (SouthernBiotech). Images were collected with
an AxioVision confocal microscope and light microscope (Zeiss)
and processed with ImageJ19 and Illustrator CS4 (Adobe Systems).Immunoblot and Co-immunoprecipitation Analyses
For whole-cell immunoblotting, resuspended cell pellets were ex-
tracted with RIPA lysis buffer (150 mM NaCl, 0.1% Triton X-100,
0.5% sodium deoxycholate, 0.1% SDS, and 50 mM Tris-HCl
[pH 8.0]) and protease inhibitors (cOmplete Mini, Roche). For sub-
cellular fractionation, cells were washed in PBS and resuspended in
isotonic mitochondria-isolation buffer (10 mM Tris/MOPS,
200 mM sucrose, and 1 mM EGTA/Tris [pH 7.4]) as previously
described20 and then homogenized by 20 strokes with a
Teflon pestle in a glass potter. The suspension was centrifuged at
600 3 g for 10 min at 4C. The supernatant was centrifuged at
10,000 3 g for 20 min at 4C for separating the mitochondrial
fraction (pellet) from the cytosolic fraction (supernatant). The
mitochondria were washed once with the isotonic buffer, and
the cytosolic fraction was centrifuged at 16,000 3 g for 20 min
at 4C for removal of any residual mitochondria. Mitochondria
were lysed in the RIPA lysis buffer with protease inhibitors.The AmThe samples were separated on SDS-PAGE, blotted on a polyvi-
nylidene fluoride membrane, and probed with antibodies against
the following: PYCR2 (LS-C115748, LsBio; 1:200), V5 (R960-25,
Life Technologies; 1:5,000), GFP (ab13970, Abcam; 1:5,000),
IkBa (ab32518, Abcam; 1:1,000), VDAC1 (ab154856, Abcam;
1:1,000), b-actin (ab8227, Abcam; 1:1,000), SDHA (ab14715,
Abcam; 1:1,000), and MT-CO2 (ab79393, Abcam; 1:500). Blots
were scanned on a Li-Cor Odyssey imager. Signal intensities
were quantified with Image Studio Lite (Li-Cor).
For co-immunoprecipitation, HEK293FT cells were transfected
with one of the following combinations: (1) cDNAs encoding
HA-tagged and V5-tagged wild-type PYCR2, (2) cDNAs encoding
HA-tagged and V5-tagged p.Arg251Cys variant PYCR2, or (3) a
control EGFP expression vector (pEGFP-C1, Clontech). After
48 hr, cells were washed once with PBS and then incubated with
the chemical crosslinker dithiobis (succinimidyl propionate)
(Thermo Scientific) at a 1.5 mM concentration in PBS for
30 min. The reaction was quenched with 100 mM Tris-HCl for
15 min. Cells were then lysed with RIPA lysis buffer, and small
amounts of lysates were reserved as input fractions. The remaining
portions of lysates were incubated with pre-washed monoclonal
anti-HA agarose conjugate resin (Sigma-Aldrich) overnight on a
shaker at 4C. The resin beads were washed four times with RIPA
buffer and resuspended in 23 reducing SDS sample buffer. All sam-
ples were boiled at 98C for 10 min and then briefly vortexed, and
supernatants were applied to immunoblotting. Immunoblotting
was performed as described above with antibodies for HA
(11867423001, Roche; 500 ng/ml), V5 (R960-25, Life Technolo-
gies; 1:1,000), and b-actin (ab8227, Abcam; 1:1,000). The experi-
ment was repeated twice.Apoptosis Assay
Cells were washedwith 37C PBS once and incubated with 400 mM
hydrogen peroxide (H1009, Sigma-Aldrich) for 1 hr without FBS.
Subsequently, medium was replaced with DMEM with 10% FBS,
and cells were incubated for an additional 24 hr. Cells were then
washed with PBS-G twice, fixed in 4% (w/v) paraformaldehyde
in PBS for 15 min, and permeabilized with 0.1% (w/v) Triton
X-100 in PBS for 5 min at room temperature. A TUNEL assay
(Click-iT, Life Technologies) was performed according to the man-
ufacturer’s instruction. Cells were then stained with Hoechst
33342 and mounted in Fluoromount-G (SouthernBiotech).
Images were collected with an AxioVision confocal microscope
and light microscope (Zeiss) and processed with ImageJ19 for cell
counting. More than 3,000 cells were analyzed per experiment,
and each experiment was repeated twice. Statistical analysis was
performed with SPSS Statistics 22 (IBM).Zebrafish Morpholino Experiments
Zebrafish were maintained according to animal research guide-
lines at Boston Children’s Hospital. Morpholino oligonucleotides
(MOs; Gene Tools) that interfere with translation of pycr1a
(RefSeq accession number NM_200826.1) and pycr1b (RefSeq
NM_001020618.1) by blocking the start codon were modified
from previously described constructs.21 The sequences of the de-
signed MOs for pycr1a and pycr1b were 50-GCTCCGATAAATCCCA
CACTCATTC-30 and 50-GCTCCAATGAAGCCCACACTCATCC-30,
respectively. The MOs were resuspended in sterile water to a con-
centration of 1 mM and were further diluted to 2.5, 3.5, and
5.0 ng/ml with phenol red and water. One nanoliter of each MO
solution was injected into 1- to 2-cell-stage zebrafish embryos.erican Journal of Human Genetics 96, 709–719, May 7, 2015 711
Table 1. Clinical Presentation of the Affected Individuals with PYCR2 Mutations
Family MR900 Family MC27800
MR901 MR902 MC27801 MC27802
Parental consanguinity yes (first cousins) yes (first cousins) yes (first cousins) yes (first cousins)
Gender male female female female
Age at examination 11 years, 6 months 10 years, 3 months 9 years, 5 months 7 years, 8 months
Head circumference
at birth
NA NA 35 cm (þ0.2 SD) 34 cm (0.5 SD)
Head circumference
at examination
43.6 cm (7.0 SDs) 42.6 cm (7.7 SDs) 44 cm (6.6 SDs) 46 cm (4.5 SDs)
Length 88 cm (4.6 SDs) at 5 years,
2 months
80 cm (4.8 SDs) at 3 year,
11 months
92 cm (2.0 SDs) at 3 years,
11 months
83 cm (1.3 SDs) at
2 years, 2 months
Weight 10.8 kg (3.7 SDs) at 4 years,
6 months
8.3 kg (4.4 SDs) at 3 years,
6 months
10 kg (3.5 SDs) at 3 years,
11 months
9 kg (3.0 SDs) at
2 years, 2 months
Motor development crawled on chest but is now
bedridden
sat with support and crawled
at 14 months but is now
mostly bedridden
does not roll over or sit
unsupported
rolls over and sits
with support
Speech and cognition babbled and responded to name
but now shows little response to
stimuli; no words
babbled at 8 months; no
words
recognizes parents with social
smile; no words
recognizes parents
with social smile;
no words
Motor examination severe muscle wasting,
hypertonia, brisk DTRs
severe muscle wasting,
hypertonia, brisk DTRs
severe muscle wasting, limited
range of motion of the hips and
knees, hyperextensibility of wrists
and ankles, brisk DTRs
severe muscle wasting,
hyperextensibility of
the wrists and ankles,
brisk DTRs
Facial features down-slanting eyes, prominent
eyelashes, thin vermilion of the
lips
prominent eyelashes, thin
vermilion of the lips
up-slanting eyes, bulbous nasal
tip, protuberant ears with
hypoplastic antihelix
down-slanting eyes,
blunted nasal tip,
prominent jaw
Other findings exotropia, undescended testicles,
type 1 diabetes, gastrostomy tube
poor dentition, malformed
teeth
large atrial septal defect,
gastrostomy tube
none reported
MRI Findings
Age at MRI 4 years, 0 months 3 years, 4 months 2 years, 7 months 1 year, 10 months
Myelination hypomyelination hypomyelination hypomyelination hypomyelination
White-matter volume markedly diminished markedly diminished markedly diminished markedly diminished
Corpus callosum thin thin very thin very thin
Brain stem thin slightly thin slightly thin slightly thin
Abbreviations are as follows: DTR, deep tendon reflex; NA, not available.A standard control MO against b-globin (Gene Tools) was used at
the same concentrations and volume as those of the experimental
MOs. Injected embryos and uninjected clutch-mate controls were
analyzed at 0, 1, 2, 3, and 4 days post-fertilization (dpf) for sur-
vival, motility, and morphology. For the head-width measure-
ment, 20 morphant larvae and 20 control larvae were randomly
selected at 4 dpf, and the maximum head width was measured
by an investigator blinded to the injection procedure. For rescue
experiments, human PYCR2 cDNA was transcribed in vitro with
a T7 Kit (Ambion), and 20 pg of the resulting mRNA was co-
injected with MOs.
Zebrafish Histology
For histology analysis, zebrafish embryos (4 dpf) were anesthetized
on ice and fixed inmodified Karnovsky fixative (2% paraformalde-
hyde and 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer
[pH 7.4]) for 2 hr, rinsed twice in 0.1 M sodium cacodylate buffer,
and incubated in 2% osmium tetroxide in 0.1 M sodium cacody-712 The American Journal of Human Genetics 96, 709–719, May 7, 2late buffer for 2 hr. After rinsing in cacodylate buffer, fish were de-
hydrated in a graded ethanol series and embedded in TAAB 812
Resin (Canemco & Marivac). After polymerization at 60C, semi-
thin sections (0.5 mm) were prepared and stained with toluidine
blue. Images were collected with a light microscope (E800, Nikon)
and processed with ImageJ19 and Illustrator CS4 (Adobe Systems).Results
Clinical Presentation
A summary of clinical findings is presented in Table 1.
Family MR900 is a consanguineous Omani family with
two children affected by microcephaly and intellectual
disability (Figure 1A). The proband (MR901) was born at
full term by spontaneous vaginal delivery. Developmental
delay and hypertonia of the limbs were noted at 5 months015
of age. When he was 11 months old, his occipital frontal
circumference (OFC) was 42 cm (3.3 SDs). At 1 year of
age, he sat with support, crawled, and responded to his
name with a social smile, but subsequently he regressed
developmentally. He developed type 1 diabetes with posi-
tive anti-GAD antibody at 4 years of age and was started
on insulin. At 4 years and 6 months of age, he weighed
10.8 kg (3.7 SDs). When he was 5 years and 2 months
old, his OFC was 44 cm (5.2 SDs), and his length was
88 cm (4.6 SDs). When he was 11 years old, his OFC
was 43.6 cm (7.0 SDs). He was cachectic and hadminimal
interaction with his surroundings. He had generalized hy-
pertonia with increased deep tendon reflexes and bilateral
extensor plantar responses. His plasma amino acid profile
was not indicative of an inborn error of metabolism. Blood
lactate and ammonia were normal. His sister (MR902) had
a similar clinical course. She was born at full term after an
uneventful pregnancy and delivery. Reportedly, she was
doing well until 8 months of age, when she presented
with anorexia and weight loss. Subsequently, she was
noted to show microcephaly and global developmental
delay. At 3 years and 6 months of age, she weighed
8.3 kg (4.4 SDs). When she was 3 years and 11 months
of age, her OFC was 42 cm (4.9 SDs), and her length
was 80 cm (4.8 SDs). When she was 10 years old, her
OFC was 42.6 cm (7.7 SDs). She was cachectic andmostly
bedridden and showed limited social interaction. She also
had generalized hypertonia, increased deep tendon re-
flexes, and extensor plantar responses.
Family MC27800 is from Palestine, and similarly, two
siblings presented with microcephaly and intellectual
disability (Figure 1A). The proband (MC27801) was born
at full term with transient fetal distress during delivery.
Her OFC at birth was 35 cm (þ0.2 SD). She showed general
hypotonia and was slow in acquiring developmental mile-
stones. A large atrial septal defect was surgically closed
when she was 2 years old. When she was examined at
3 years and 11 months of age, her OFC was 42 cm
(4.9 SDs), her length was 92 cm (2.0 SDs), and her
weight was 10 kg (3.5 SDs). She was not able to sit and
did not speak, but she showed some social interaction.
No obvious regression was noted at that time. Neurological
examination was remarkable for generalized hypertonia.
When she was examined at 9 years and 5 months of age,
her OFC was 44 cm (6.6 SDs). She could not roll over,
sit, or speak but recognized her parents and responded by
smiling or laughing. She had severe muscle wasting, and
her hip and knees showed limited range of motion, but
her wrist and ankle joints showed hyperextensibility.
Deep tendon reflexes were increased. Her blood lactate,
plasma amino acids, and urine organic acids were normal.
Her sister (MC27802) was delivered at full term by
Caesarean section after an uncomplicated pregnancy, and
her OFC at birth was 34 cm (0.5 SD). She presented
with global developmental delay. She never achieved
sitting, crawling, or standing, but no apparent regression
was noted. Examination at 2 years and 2 months of age re-The Amvealed an OFC of 43.2 cm (3.1 SDs), length of 83 cm
(1.3 SDs), and weight of 9 kg (3.0 SDs). She followed
objects visually but did not speak. Neurological examina-
tion was remarkable for truncal hypotonia and appendic-
ular hypertonia. When she was examined at 7 years and
8 months of age, her OFC was 46 cm (4.5 SDs). She was
able to roll over and sit with support but did not speak.
She recognized her parents and responded by smiling or
laughing. She had severe muscle wasting. Her wrist and
ankle joints showed hyperextensibility, and deep tendon
reflexes were increased.
There were minor facial dysmorphisms, but no consis-
tent features among the affected individuals were noted
(Figure 1B and Table 1). None of the affected individuals
had notable skin findings. All affected individuals
underwent brain MRI, which revealed similar features,
including microcephaly with decreased cerebral white-
matter volume (with associated thin corpus callosum,
thin brain stem, and mild ventriculomegaly) and signifi-
cant hypomyelination (Figure 1C). The cerebellum was
unremarkable.
Identifying PYCR2 Mutations by Linkage Mapping
and Whole-Exome Sequencing
Because of the similar clinical presentation and consan-
guinity in each family, we hypothesized that the two fam-
ilies were affected by the same allelic autosomal-recessive
condition. We performed genome-wide SNP analysis of
both families and found that the four affected individuals
from both families shared a genomic region of homozygos-
ity on chromosome 1q. This was the only homozygous re-
gion shared by all affected individuals and was over 1 cM.
The region was delineated by SNP markers rs2405523 and
rs10802533 and was 11.6 Mb in size. The haplotypes were
different between the two families. We also calculated a
combined genome-wide LOD score for both families and
obtained a maximummultipoint LOD score of 3.72 within
the candidate region on chromosome 1q (Figure 2A). No
other region in the genome had a LOD score over 1.0.
Next, we performed whole-exome sequencing on two
affected individuals (MR901 and MC27801), one from
each family. We filtered the identified variants for call qual-
ity, homozygosity, potential pathogenicity, population fre-
quency, and localization within the candidate interval.
Individuals MR901 and MC27801 were found to have
three and two rare candidate variants, respectively (Table
S2). Only one gene was shared by both individuals, and
this was PYCR2 (RefSeq NM_013328.3), which encodes
pyrroline-5-carboxylate reductase 2 (PYCR2). The variants
were homozygous c.355C>T (p.Arg119Cys) in individual
MR901 and homozygous c.751C>T (p.Arg251Cys) in indi-
vidual MC27801 (Figure 2B). The residue Arg119 is located
in the NADH-binding domain, and the residue Arg251 is
in the dimerization domain of PYCR2 (InterPro). We
confirmed these variants by Sanger sequencing, and
they segregated with the disease in each family (Fig-
ure 2C). Both variants were predicted to be damaging byerican Journal of Human Genetics 96, 709–719, May 7, 2015 713
Figure 2. Linkage Mapping and Identification of PYCR2 Mutations
(A) Genome-wide LOD scores combined for the two families show the only significant linkage region to be 1q42, which has a maximum
multipoint LOD score of 3.72.
(B) Schematic representation of the PYCR2 variants. Residue Arg119 is in the NAD(P)-binding domain, and residue Arg251 is in the
dimerization domain.
(C) Sanger sequencing confirmed the identified variants in family MR900 (c.355C>T [p.Arg119Cys]) and family MC27800 (c.751C>T
[p.Arg251Cys]). These variants segregated with the disease phenotype in each family. Positions of variants are according to RefSeq
NM_013328.3 (cDNA) and RefSeq NP_037460.2 (protein).PolyPhen-2,22 SIFT,23 and PROVEAN,24 suggesting their
pathogenicity (Table S3). We also searched for additional
deleterious PYCR2 alleles in our database of 82 exomes
from individuals with microcephaly, but we did not find
other convincing disease-causing mutations.
Expression of PYCR2 in the Developing Human Brain
To understand the function of PYCR2 in the human brain,
we first analyzed RNA sequencing data of fetal human
brain at Carnegie stage 18. We found that PYCR2 mRNA
was moderately expressed in the developing human brain
(Figure S1) and that its level of expression was much
greater than that of PYCR1 (MIM 179035) and PYCRL,
genes encoding PYCR2 isozymes.
PYCR2 Variants Lead to Reduced PYCR2 Levels
We established a lymphoblastoid cell line from one of the
affected individuals (MR901) with the homozygous
p.Arg119Cys variant and performed immunoblot analysis
of PYCR2. The PYCR2 level was markedly lower in this
cell line than in a control cell line (Figures 3A and 3B). In
order to further assess the effect of the PYCR2 variants
that we identified, we transfected HEK293FT cells with
wild-type and mutant PYCR2 cDNA and measured the re-
sulting PYCR2-V5 levels. Compared to cells transfected
with wild-type PYCR2, cells transfected with mutant
PYCR2 showed a marked decrease in the amount of variant
protein with the p.Arg119Cys substitution and a small
decrease in the amount of variant protein with the
p.Arg251Cys substitution (Figure 3C). This was confirmed
quantitatively by immunoblot analysis, in which the
PYCR2-V5/EGFP intensity ratios were measured to adjust
for transfection efficiency (Figures 3D and 3E).
Because residue Arg251 is in the dimerization domain,
we also performed a co-immunoprecipitation assay to
test whether the variant p.Arg251Cys would affect homo-714 The American Journal of Human Genetics 96, 709–719, May 7, 2dimerization of PYCR2. Wild-type HEK293FT cells were
transfected with both HA-tagged and V5-tagged PYCR2
cDNA (wild-type or c.751C>T mutant, which encodes
p.Arg251Cys). The lysates were immunoprecipitated with
anti-HA antibody beads and were blotted with anti-HA
and anti-V5 antibodies. Wild-type PYCR2 showed an
abundant signal with anti-V5 antibody, suggesting robust
homodimerization. The p.Arg251Cys variant PYCR2 also
showed a strong signal with anti-V5 antibody, though to
a lesser extent (Figure S2). These data suggest that the
p.Arg251Cys variant does not completely abolish the abil-
ity of PYCR2 to form a homodimer.
Human PYCR2 Localizes to Mitochondria
To investigate the cellular function of PYCR2, we created a
PYCR2-deficient HEK293FT cell line by using the CRISPR-
Cas9 system.We introduced a homozygous, 1-bp insertion
expected to lead to a frameshift and premature truncation
(c.737_738insA [p.Ser247Glufs*13]; Figure S3A) into the
PYCR2 coding region. Immunoblot analysis of fractionated
lysates from wild-type and mutant HEK293FT cells re-
vealed that endogenous PYCR2 localized to the mitochon-
drial fraction in wild-type cells but was absent frommutant
cells (Figure S3B). Immunocytochemistry of wild-type and
mutant cells similarly showed that PYCR2 localized to
mitochondria in wild-type cells, whereas the level of
PYCR2 was negligible in cells with mutant PYCR2
(Figure S3C). Of note, MitoTracker, the membrane-poten-
tial-dependent mitochondrial marker used, displayed
markedly weaker staining in cells with mutant PYCR2.
Mitochondrial localization of PYCR2 was also confirmed
by transfection of PYCR2 cDNA (Figure S4). Both the
p.Arg119Cys and p.Arg251Cys variant PYCR2 proteins
also localized to mitochondria, but interestingly the
MitoTracker signal was also much weaker when the
mutant cDNAs were transfected.015
Figure 3. Effect of PYCR2 Mutations
(A) Immunoblot analysis of PYCR2 levels in lymphoblastoid cell lines. Cells from an affected individual (MR901) showed a marked
reduction of PYCR2, whereas cells from his father (MR904) showed a mild reduction.
(B) Quantification of PYCR2 levels. The PYCR2/b-actin intensity ratios for MR901 and MR904 were measured in relation to that of the
control subject.
(C) Abundance of wild-type (WT) and variant (p.Arg119Cys and p.Arg251Cys) PYCR2 in transfected HEK293FT cells. The cells were
transfected with a wild-type or mutant human PYCR2 cDNA construct with a C-terminal V5 tag, along with a separate EGFP construct.
Immunostaining for V5 showed an almost undetectable level of the p.Arg119Cys variant protein and mildly decreased level of the
p.Arg251Cys variant protein. The scale bar represents 20 mm.
(D) Immunoblot analysis of PYCR2 and EGFP levels in transfected HEK293FT cells showed a dramatic reduction of the p.Arg119Cys
variant protein and a mild reduction of the p.Arg251Cys variant protein. EGFP served as a transfection control.
(E) Immunoblot analysis was quantified by comparison of the PYCR2-V5/EGFP intensity ratio between the variants proteins and the
wild-type protein. The data were averaged from three independent experiments. The p.Arg119Cys variant showed less than 2% of
the wild-type abundance. Although the p.Arg251Cys variant did not reach statistical significance, it showed a trend toward abundance
lower than wild-type abundance. Error bars represent the SD. ***p < 0.001.Given the role of PYCR2 in proline biosynthesis, we
sought to investigate whether the PYCR2-deficient cells
would show defective protein synthesis in mitochondria.
Thus, in wild-type and PYCR2-deficient cells, we measured
the abundance of two components of the oxidative phos-
phorylation enzyme complex, MT-CO2 and SDHA, which
are encoded by mitochondrial DNA and nuclear DNA,
respectively. Immunoblotting revealed that there was no
significant difference in the abundance of these proteins
between wild-type and PYCR2-deficient cells, suggesting
that loss of PYCR2 does not lead to a gross defect in mito-
chondrial protein synthesis (Figure S5).
Loss of Function of PYCR2 Leads to Increased
Apoptosis under Oxidative Stress
Progressive microcephaly and reduced white matter in the
affected individuals reported herein could suggest ongoing
cell death in the CNS. Considering that mitochondria have
been implicated in the regulation of apoptosis (reviewed in
Wang and Youle25), we sought to test the possibility that
the loss of PYCR2 function might impair this regulation
by performing a TUNEL assay with wild-type HEK293FT
cells and the CRISPR-Cas9-engineered PYCR2-deficient
cells. TUNEL staining revealed no significant difference
in apoptosis between the wild-type and PYCR2-deficient
cell lines under normal culture conditions (data not
shown). However, 1 hr of incubation in 400 mM hydrogenThe Amperoxide led to more TUNEL-positive cells in the mutant
cell lines than in wild-type cells (Figures 4A and 4B), indi-
cating that PYCR2 is involved in the cell’s response to
oxidative stress.
Zebrafish Morpholino Knockdown of a PYCR2
Ortholog Recapitulates Human Microcephaly
To investigate the role of PYCR2 during brain develop-
ment, we performed zebrafish gene-knockdown experi-
ments targeting PYCR2 orthologs. PYCR2 has two zebrafish
orthologs, pycr1a (RefSeq NM_200826.1) and pycr1b
(RefSeq NM_001020618.1), and they share comparable ho-
mology to human PYCR2. We first attempted to knock
down each of pycr1a and pycr1b by usingMOs. Knockdown
of pycr1b resulted in a small head, whereas knockdown of
pycr1a led to a previously described skin phenotype (loos-
ening of epidermis),21 but the effect on the head size was
less noticeable. Therefore, we focused subsequent analysis
on pycr1b.
When embryos were injected with 3.5 ng of the pycr1b
MO, approximately one-third of the morphant larvae at
4 dpf appeared severely affected by a small head and
eyes, short body, a down-tilted tail, and hypomotility,
whereas nearly two-thirds of the morphants showed a
milder phenotype of a small head and eyes and hypomotil-
ity (Figure 5A and Figure S6). These phenotypic effects
were dose dependent. Small head size was evident byerican Journal of Human Genetics 96, 709–719, May 7, 2015 715
Figure 4. PYCR2 Loss of Function In-
creases Apoptosis under Oxidative Stress
(A) HEK293FT cells were treated with
400 mM H2O2 for 1 hr, followed by 24 hr
in culture. The mutant cells, harboring a
homozygous frameshift mutation (PYCR2
mutant), showed more apoptosis than
did wild-type cells, as detected by TUNEL
assay. The scale bar represents 200 mm.
(B) Quantification of TUNEL assay re-
vealed a statistically significant increase
in apoptosis of the mutant cells treated
with H2O2. Data were averaged from
two independent experiments. Error bars
represent the SD. **p < 0.01.1 dpf (Figures S7A and S7B) and became more obvious at
later stages. The maximum head width measured for mor-
phant larvae at 4 dpf was significantly smaller than that of
controls (Figures 5A and 5B). Histological sections of the
brains of morphant larvae were consistent with a smaller
brain size affecting the forebrain, midbrain, and hindbrain
(Figures 5C and 5D). There were no obvious skin defects
observed in pycr1b morphants.
Finally, we performed rescue experiments with human
PYCR2 mRNA. When wild-type human PYCR2 mRNA
was co-injected with the pycr1b MO, the microcephaly
phenotype was rescued (Figures 5A and 5B and Figure S7C).
On the other hand, almost no rescue was observed with
human PYCR2 mRNA harboring the c.355C>T variant,
and only partial rescue was noted with the c.751C>T
variant (Figure 5B). These results further support the
pathogenicity of the identified PYCR2 variants.Discussion
Herein, we have shown that mutations in PYCR2, which
encodes an enzyme in the proline biosynthesis pathway,
lead to a phenotype of microcephaly with cerebral hypo-
myelination in humans. In four affected individuals from
two unrelated consanguineous families, we identified two
mutant PYCR2 alleles that are predicted to affect protein
function. We took advantage of the newly developed
CRISPR-Cas9 system to generate a cellular model of
PYCR2 loss of function and showed that deficiency of
PYCR2 resulted in increased apoptosis under oxidative
stress. Knockdown of a zebrafish PYCR2 ortholog, pycr1b,
recapitulated the microcephaly phenotype, which was
rescued by wild-type human PYCR2 mRNA, but not
by mRNAs harboring the human mutations. Together,
these results support the pathogenicity of the identified
PYCR2 mutations and suggest that mitochondria-induced
apoptosis in the CNS is a potential mechanism for micro-
cephaly in these affected individuals.
PYCR2 is one of three human pyrroline-5-carboxylate
reductases (PYCRs) that catalyze the reduction of D1-pyrro-
line-5-carboxylate (P5C) toprolinewhileoxidizingNAD(P)H716 The American Journal of Human Genetics 96, 709–719, May 7, 2to NAD(P)þ.26,27We showed that the two identified variants
in PYCR2 occur at highly conserved amino acids and that
the levels of the altered proteins were lower in transfected
cells, suggesting that these two variants affect the stability
of the resulting PYCR2.
Several genetic disorders affecting proline biosynthesis
have been described. Interestingly, mutations in PYCR1,
encoding an isozyme of PYCR2, cause autosomal-recessive
cutis laxa with progeroid features, including autosomal-
recessive cutis laxa type IIB (MIM 612940) and type IIIB
(MIM 614438).21 Of note, some of the reported pathogenic
PYCR1 variants are at Arg119 and Arg251, the residues
corresponding to the mutated regions in PYCR2 in the
individuals described herein. The clinical features of indi-
viduals with PYCR1mutations include wrinkled skin, joint
hyperlaxity, characteristic facial features including a trian-
gular face, short nose, long philtrum, and large ears, mild
to moderate microcephaly, and psychomotor retarda-
tion.28 Although information on brain-imaging findings
is limited, some individuals with PYCR1 mutations have
been reported to have an abnormal corpus callosum and
enlarged ventricles, but abnormalities of myelination
have not been reported.29,30 In contrast, individuals
affected by PYCR2 mutations do not present with cutis
laxa and show evidence of significant hypomyelination
on brain MRI. There is some phenotypic overlap between
PYCR1 and PYCR2 mutations in terms of microcephaly
and global developmental delay, as well as joint hyperlax-
ity, which was noted only in family MC27800. However,
they seem to cause clinically distinct conditions, and mu-
tations in PYCR2 appear to lead to a syndrome of micro-
cephaly and hypomyelination.
The different phenotypes caused by the PYCR1 and
PYCR2 variants suggest that each of these isozymes has a
unique role in the human body. Both PYCR1 and PYCR2
are thought to localize to mitochondria and primarily
act in the conversion of glutamate to proline.26 Another
isozyme, PYCRL, is thought to localize to the cytosol and
primarily be involved in converting ornithine to proline.
We observed that PYCR2mRNAwasmore highly expressed
than PYCR1 and PYCRL in the developing human brain,
and so different spatial and temporal expression patterns015
Figure 5. Morpholino-Based Knock-
down of Zebrafish pycr1b Recapitulates
the Human Microcephaly Phenotype
(A) Compared to zebrafish injected with
control MO (control MO), 4-dpf zebrafish
larvae injected with 3.5 ng pycr1b MO at
the 1- to 2-cell stage (pycr1bMO) showed a
smallhead size (horizontalwhitebars repre-
sent the maximum head width measured)
and a curved tail. Co-injection of human
PYCR2mRNA (hPYCR2WT; 20 pg) rescued
the phenotype. The scale bar represents
100 mm. Representative images are shown.
(B) Measurements of the maximum head
width of pycr1b morphants were signifi-
cantly smaller than those of the control.
Co-injection of human PYCR2 mRNA
(hPYCR2 WT) rescued the phenotype, but
mutant mRNAs (hPYCR2 c.355C>T and
hPYCR2 c.751C>T) failed to show a full
rescue effect. Twenty larvae for each
category were randomly selected for mea-
surement of the maximum head width
illustrated in (A). Bars represent the mean
value and SEM. ***p < 0.001.
(C and D) Sagittal brain sections of larvae
injected with control MO (C) or pycr1b
MO (D) at 4 dpf were stained with tolui-
dine blue. The size of the forebrain,
midbrain, and hindbrain was significantly
smaller in the pycr1bmorphant than in the
control. Scale bars represent 100 mm.could in part explain the differences in the resulting clin-
ical phenotypes. However, there might be other biological
reasons for the distinct phenotypes. For example, enzy-
matic properties of PYCR1 and PYCR2 have been reported
to be different: PYCR2 has been shown to be more catalyt-
ically efficient than PYCR1 in the presence of NADH, and
at the same time, PYCR2 has been shown to be more
susceptible to product inhibition.26 Thus, PYCR1 and
PYCR2 could play overlapping, yet non-redundant roles
in mitochondrial physiology.
Although PYCR2 is an enzyme for proline biosynthesis,
systemic deprivation of proline does not appear to be the
pathogenetic mechanism of this condition, given that
plasma amino acid analysis in two affected individuals
did not show low proline levels. Furthermore, we showed
that mitochondrial protein synthesis was not affected in
PYCR2-deficient cells. Therefore, deficiency of proline, as
a building block of proteins, might not be the major path-
ophysiology. However, proline has been reported as a non-
enzymatic antioxidant that suppresses apoptosis,31 and
therefore local proline biosynthesis in neurons might
be important for neuronal protection against oxidative
stress. In the current study, we demonstrated that engi-
neered PYCR2-deficient cells displayed significantly more
apoptosis than wild-type cells under oxidative stress, sug-
gesting the involvement of PYCR2 in the cellular response
to oxidative stress. In addition, a membrane-potential-
dependent mitochondrial marker displayed much weaker
staining in the PYCR2-deficient cells, indicating that
PYCR2 is essential in maintaining mitochondrial mem-The Ambrane potential. It is also important to note that the reac-
tion catalyzed by PYCRs leads to both a reduction of P5C
to proline and oxidation of NAD(P)H to NAD(P)þ, and so
PYCRs might also be involved in regulating NAD(P)H
and NAD(P)þ, molecules that have been implicated in
neuronal cell death (reviewed in Ying32).
The pathogenesis of hypomyelination in the individuals
with PYCR2mutations is not immediately clear. Previously
reported genes mutated in conditions with hypomyelina-
tion encode proteins with diverse functions, but they do
not obviously share biological pathways with PYCR2. Mye-
lination is an energy-expensive process, and energy depri-
vation negatively affects oligodendrocyte development
and myelination.33 In addition, involvement of cerebral
white matter can be seen in individuals with mitochon-
drial encephalopathies.34 Therefore, energy failure in oli-
godendrocytes is one plausible mechanism.
In summary, we identified mutations in PYCR2 as the
cause of a genetic disorder characterized by microcephaly
and hypomyelination. We demonstrated that PYCR2-defi-
cient cells showed increased apoptosis under oxidative
stress, and therefore postnatal microcephaly in affected
individuals is most likely due to increased cell death in
the CNS.Supplemental Data
Supplemental Data include seven figures and three tables and can
be found with this article online at http://dx.doi.org/10.1016/j.
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